(Q40649739)

English

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

scientific article published on June 1997

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 September 2017

Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

22 September 2017

author name string

C Manegold

1

1 reference

Europe PubMed Central

22 September 2017

B Bergman

2

1 reference

Europe PubMed Central

22 September 2017

A Chemaissani

3

1 reference

Europe PubMed Central

22 September 2017

W Dornoff

4

1 reference

Europe PubMed Central

22 September 2017

P Drings

5

1 reference

Europe PubMed Central

22 September 2017

P Kellokumpu-Lehtinen

6

1 reference

Europe PubMed Central

22 September 2017

K Liippo

7

1 reference

Europe PubMed Central

22 September 2017

K Mattson

8

1 reference

Europe PubMed Central

22 September 2017

J van Pawel

9

1 reference

Europe PubMed Central

22 September 2017

S Ricci

10

1 reference

Europe PubMed Central

22 September 2017

C Sederholm

11

1 reference

Europe PubMed Central

22 September 2017

R A Stahel

12

1 reference

Europe PubMed Central

22 September 2017

G Wagenius

13

1 reference

Europe PubMed Central

22 September 2017

N van Walree

14

1 reference

Europe PubMed Central

22 September 2017

W ten Bokkel-Huinink

15

1 reference

Europe PubMed Central

22 September 2017

publication date

1 June 1997

1 reference

Europe PubMed Central

22 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

22 September 2017

8

1 reference

Europe PubMed Central

22 September 2017

525-529

1 reference

Europe PubMed Central

22 September 2017

6

1 reference

Europe PubMed Central

22 September 2017

Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for adenocarcinoma of the lung (WHO III): A randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008207731111

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008207731111

1 reference

Europe PubMed Central

22 September 2017

1 reference

Europe PubMed Central

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40649739&oldid=1904128828"